Analytical Data
-
Gene name
ADRa2C
- Application
-
Alternative Names
ADRa2C；ADRA2L2；ADRA2RL2；Alpha-2C adrenergic receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P18825
-
Expression Region
1-462aa
-
AA Sequence
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGFLIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFGQVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISAVISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLRTRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGALRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRRRRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFKFFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ
-
Molecular Weight
49.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ADRa2C is a subtype of the alpha-2 adrenergic receptor, which plays a crucial role in the modulation of neurotransmitter release and functions within the central and peripheral nervous systems. Research into ADRa2C has gained momentum due to its involvement in various physiological processes, including blood pressure regulation, sedation, and pain modulation. Given its significant role in pharmacological responses, ADRa2C has emerged as a potential therapeutic target for several conditions, such as hypertension, depression, and anxiety disorders. The development of recombinant ADRa2C proteins is vital for biochemical and pharmacological studies, enabling researchers to explore receptor structure, signaling pathways, and drug interactions in greater depth. By using advanced techniques like molecular cloning and protein expression systems, scientists can produce functional ADRa2C proteins that facilitate high-throughput screening of potential ligands and drugs. Understanding the receptor's structure-function relationship is key to designing more effective drugs with fewer side effects. Furthermore, the study of ADRa2C also contributes to the broader field of GPCR (G protein-coupled receptor) research, helping to elucidate the mechanisms underlying receptor activation and signal transduction. Through the exploration of ADRa2C, researchers aim to uncover novel insights into its biological roles and therapeutic potential, advancing the understanding of adrenergic signaling and its implications in health and disease.
